Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan

Takahiro Kojima, Hiroyuki Nishiyama, Seiichiro Ozono, Shiro Hinotsu, Naoto Keino, Akito Yamaguchi, Hideki Sakai, Yutaka Enomoto, Shigeo Horie, Kiyohide Fujimoto, Hideyasu Matsuyama, Takehiko Okamura, Yusuke Kanimoto, Mototsugu Oya, Norio Nonomura, Seiji Naito, Hideyuki Akaza

研究成果: Article

4 引用 (Scopus)

抄録

Background: We evaluated the use of UroVysion fluorescence in situ hybridization tests to detect the intravesical recurrence of bladder cancer during follow-up after a transurethral resection of bladder tumor (TURBT). Methods: In this prospective, blinded, comparative study, 486 patients treated by TURBT within the prior 2 years were registered at 12 centers. Urine cytology and UroVysion tests were performed once or twice at a central testing laboratory. For the patients with no suspicious findings of bladder cancer in the first analysis, the same examination set was repeated 3 months later as the second analysis. Totals of 468 and 399 patients were eligible for the first and second analyses, respectively. We determined the sensitivity and specificity of two consecutive UroVysion tests. Results: Bladder cancers were identified in 44 patients at the first analysis. The UroVysion test had 50.0% (95% CI 35.2–64.8%) sensitivity and 72.4% (68.3–76.8%). Urine cytology had 4.5% (0.0–10.7%) sensitivity and 99.8% (99.3–100.0%) specificity. The concordant rate of the first and second UroVysion test results was 72% (kappa coefficient 0.157). Interestingly, the patients with two consecutive positive UroVysion test results had the highest cancer detection rate (14.8%), which is greater than those of the patients with a positive result in either (7.2%) or neither (1.2%) of the two tests at the 3-month follow-up. Conclusions: The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence.

元の言語English
ページ(範囲)1-8
ページ数8
ジャーナルInternational Journal of Clinical Oncology
DOI
出版物ステータスAccepted/In press - 2018 7 3

Fingerprint

Fluorescence In Situ Hybridization
Urinary Bladder Neoplasms
Japan
Recurrence
Cell Biology
Urine
Sensitivity and Specificity
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

これを引用

Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer : a prospective blinded comparative study in Japan. / Kojima, Takahiro; Nishiyama, Hiroyuki; Ozono, Seiichiro; Hinotsu, Shiro; Keino, Naoto; Yamaguchi, Akito; Sakai, Hideki; Enomoto, Yutaka; Horie, Shigeo; Fujimoto, Kiyohide; Matsuyama, Hideyasu; Okamura, Takehiko; Kanimoto, Yusuke; Oya, Mototsugu; Nonomura, Norio; Naito, Seiji; Akaza, Hideyuki.

:: International Journal of Clinical Oncology, 03.07.2018, p. 1-8.

研究成果: Article

Kojima, T, Nishiyama, H, Ozono, S, Hinotsu, S, Keino, N, Yamaguchi, A, Sakai, H, Enomoto, Y, Horie, S, Fujimoto, K, Matsuyama, H, Okamura, T, Kanimoto, Y, Oya, M, Nonomura, N, Naito, S & Akaza, H 2018, 'Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan', International Journal of Clinical Oncology, pp. 1-8. https://doi.org/10.1007/s10147-018-1311-6
Kojima, Takahiro ; Nishiyama, Hiroyuki ; Ozono, Seiichiro ; Hinotsu, Shiro ; Keino, Naoto ; Yamaguchi, Akito ; Sakai, Hideki ; Enomoto, Yutaka ; Horie, Shigeo ; Fujimoto, Kiyohide ; Matsuyama, Hideyasu ; Okamura, Takehiko ; Kanimoto, Yusuke ; Oya, Mototsugu ; Nonomura, Norio ; Naito, Seiji ; Akaza, Hideyuki. / Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer : a prospective blinded comparative study in Japan. :: International Journal of Clinical Oncology. 2018 ; pp. 1-8.
@article{28ee2e6808134d0e9a3400f24074f201,
title = "Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan",
abstract = "Background: We evaluated the use of UroVysion fluorescence in situ hybridization tests to detect the intravesical recurrence of bladder cancer during follow-up after a transurethral resection of bladder tumor (TURBT). Methods: In this prospective, blinded, comparative study, 486 patients treated by TURBT within the prior 2 years were registered at 12 centers. Urine cytology and UroVysion tests were performed once or twice at a central testing laboratory. For the patients with no suspicious findings of bladder cancer in the first analysis, the same examination set was repeated 3 months later as the second analysis. Totals of 468 and 399 patients were eligible for the first and second analyses, respectively. We determined the sensitivity and specificity of two consecutive UroVysion tests. Results: Bladder cancers were identified in 44 patients at the first analysis. The UroVysion test had 50.0{\%} (95{\%} CI 35.2–64.8{\%}) sensitivity and 72.4{\%} (68.3–76.8{\%}). Urine cytology had 4.5{\%} (0.0–10.7{\%}) sensitivity and 99.8{\%} (99.3–100.0{\%}) specificity. The concordant rate of the first and second UroVysion test results was 72{\%} (kappa coefficient 0.157). Interestingly, the patients with two consecutive positive UroVysion test results had the highest cancer detection rate (14.8{\%}), which is greater than those of the patients with a positive result in either (7.2{\%}) or neither (1.2{\%}) of the two tests at the 3-month follow-up. Conclusions: The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence.",
keywords = "Bladder cancer, Cytology, Fluorescence in situ hybridization, Sensitivity, Specificity, UroVysion",
author = "Takahiro Kojima and Hiroyuki Nishiyama and Seiichiro Ozono and Shiro Hinotsu and Naoto Keino and Akito Yamaguchi and Hideki Sakai and Yutaka Enomoto and Shigeo Horie and Kiyohide Fujimoto and Hideyasu Matsuyama and Takehiko Okamura and Yusuke Kanimoto and Mototsugu Oya and Norio Nonomura and Seiji Naito and Hideyuki Akaza",
year = "2018",
month = "7",
day = "3",
doi = "10.1007/s10147-018-1311-6",
language = "English",
pages = "1--8",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer

T2 - a prospective blinded comparative study in Japan

AU - Kojima, Takahiro

AU - Nishiyama, Hiroyuki

AU - Ozono, Seiichiro

AU - Hinotsu, Shiro

AU - Keino, Naoto

AU - Yamaguchi, Akito

AU - Sakai, Hideki

AU - Enomoto, Yutaka

AU - Horie, Shigeo

AU - Fujimoto, Kiyohide

AU - Matsuyama, Hideyasu

AU - Okamura, Takehiko

AU - Kanimoto, Yusuke

AU - Oya, Mototsugu

AU - Nonomura, Norio

AU - Naito, Seiji

AU - Akaza, Hideyuki

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Background: We evaluated the use of UroVysion fluorescence in situ hybridization tests to detect the intravesical recurrence of bladder cancer during follow-up after a transurethral resection of bladder tumor (TURBT). Methods: In this prospective, blinded, comparative study, 486 patients treated by TURBT within the prior 2 years were registered at 12 centers. Urine cytology and UroVysion tests were performed once or twice at a central testing laboratory. For the patients with no suspicious findings of bladder cancer in the first analysis, the same examination set was repeated 3 months later as the second analysis. Totals of 468 and 399 patients were eligible for the first and second analyses, respectively. We determined the sensitivity and specificity of two consecutive UroVysion tests. Results: Bladder cancers were identified in 44 patients at the first analysis. The UroVysion test had 50.0% (95% CI 35.2–64.8%) sensitivity and 72.4% (68.3–76.8%). Urine cytology had 4.5% (0.0–10.7%) sensitivity and 99.8% (99.3–100.0%) specificity. The concordant rate of the first and second UroVysion test results was 72% (kappa coefficient 0.157). Interestingly, the patients with two consecutive positive UroVysion test results had the highest cancer detection rate (14.8%), which is greater than those of the patients with a positive result in either (7.2%) or neither (1.2%) of the two tests at the 3-month follow-up. Conclusions: The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence.

AB - Background: We evaluated the use of UroVysion fluorescence in situ hybridization tests to detect the intravesical recurrence of bladder cancer during follow-up after a transurethral resection of bladder tumor (TURBT). Methods: In this prospective, blinded, comparative study, 486 patients treated by TURBT within the prior 2 years were registered at 12 centers. Urine cytology and UroVysion tests were performed once or twice at a central testing laboratory. For the patients with no suspicious findings of bladder cancer in the first analysis, the same examination set was repeated 3 months later as the second analysis. Totals of 468 and 399 patients were eligible for the first and second analyses, respectively. We determined the sensitivity and specificity of two consecutive UroVysion tests. Results: Bladder cancers were identified in 44 patients at the first analysis. The UroVysion test had 50.0% (95% CI 35.2–64.8%) sensitivity and 72.4% (68.3–76.8%). Urine cytology had 4.5% (0.0–10.7%) sensitivity and 99.8% (99.3–100.0%) specificity. The concordant rate of the first and second UroVysion test results was 72% (kappa coefficient 0.157). Interestingly, the patients with two consecutive positive UroVysion test results had the highest cancer detection rate (14.8%), which is greater than those of the patients with a positive result in either (7.2%) or neither (1.2%) of the two tests at the 3-month follow-up. Conclusions: The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence.

KW - Bladder cancer

KW - Cytology

KW - Fluorescence in situ hybridization

KW - Sensitivity

KW - Specificity

KW - UroVysion

UR - http://www.scopus.com/inward/record.url?scp=85049587515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049587515&partnerID=8YFLogxK

U2 - 10.1007/s10147-018-1311-6

DO - 10.1007/s10147-018-1311-6

M3 - Article

C2 - 29971622

AN - SCOPUS:85049587515

SP - 1

EP - 8

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -